Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Dragonfly Therapeutics Partners With AbbVie

Dragonfly Therapeutics and AbbVie forged a multi-target research collaboration to advance new treatment options for autoimmune and oncology indications.

Read More »

Amgen to Cut More U.S. Jobs

Amgen filed a Worker Adjustment and Retraining in California with plans to cut 172 jobs at the company’s headquarters and U.S. field operations effective December 31, 2019.

Read More »

California sues e-cigarette maker Juul

The state of California sued Juul Labs Inc., alleging the e-cigarette maker engaged in a “systematic” and “wildly successful” campaign to attract teenagers to the San Francisco company’s nicotine devices.

Read More »

Alkermes Buys Rodin Therapeutics

Dublin, Ireland-based Alkermes is acquiring Boston-based Rodin Therapeutics for $100 million up front and up to $850 million in milestone payments.

Read More »

BeiGene prices lymphoma drug at $12,935 for a 30-day supply

BeiGene Ltd. priced the China-based drugmaker’s Brukinsa to treat a rare form of lymphoma at $12,935 for a 30-day supply.

Read More »

Bristol-Myers wins antitrust approval to buy Celgene

Bristol-Myers Squibb Co. and Celgene Corp. won U.S. antitrust approval for their merger on condition that they sell Celgene’s psoriasis drug Otezla.

Read More »

Oklahoma judge reduces J&J opioid payout

An Oklahoma judge said Johnson & Johnson must pay that state $465 million for fueling the opioid epidemic through the deceptive marketing of painkillers, down from his original award of $572 million.

Read More »

Roche to Acquire Fibrosis-Focused Promedior

A year after Bristol-Myers Squibb walked away from acquiring Promedior and the company’s fibrotic treatment portfolio, Roche stepped in to acquire the biotech firm for up to $1.4 billion.

Read More »

Mylan Manufacturing Site Flagged for Poor Controls

Mylan has come under fire from the U.S. Food and Drug Administration over inadequate good manufacturing practices at one of the company’s drug manufacturing facilities in India.

Read More »

Bayer and Dewpoint Therapeutics partner to research new treatments for cardiovascular and gynecological diseases

Bayer and biotechnology company Dewpoint Therapeutics announced an option, research and license agreement worth up to $100 million.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!


Ad Right Bottom